Ascentage Pharma Group International - American Depository Shares (AAPG)

Wie das Geld verdient wird

Money comes in three ways. First, selling the two approved drugs in mainland China through an in-house commercial team of more than 270 people covering over 1,500 hospitals and more than 800 pharmacies, plus national distributors; all approved indications of Olverembatinib have been on China's National Reimbursement Drug List since January 2025, which lowers the patient's out-of-pocket cost but caps the price the company can charge. Second, commercialization rights income from Innovent, which paid US$30 million upfront in July 2021 for rights to Olverembatinib in Greater China and owes up to US$115 million more in milestones. Third, licensing income from partners abroad: Takeda paid US$100.0 million in June 2024 for an exclusive option on Olverembatinib outside Greater China and Russia, with up to roughly US$1.2 billion of possible option-exercise and milestone payments and royalties of 12–19% of net sales if the option is exercised. That third stream is lumpy: it produced RMB 678.4 million in 2024 and nothing at all in 2025, which is why total revenue fell even as product sales rose sharply. The company is not profitable and funds itself largely with equity issuance, including its January 2025 Nasdaq IPO and a July 2025 follow-on.

Umsatz nach Segment

The advantage such as it is rests on patents and regulatory position, not on scale or customer lock-in. Olverembatinib was the first BCR-ABL1 inhibitor approved in China for CML patients with the T315I mutation, it sits on the National Reimbursement Drug List for all its approved indications, and it appears in the Chinese CSCO, CACA and Chinese Medical Association treatment guidelines as well as the NCCN and European LeukemiaNet documents; Lisaftoclax is, on the company's account, the first Bcl-2 inhibitor approved in China for BTK-refractory CLL/SLL. Behind them sit 512 issued patents, 374 of them outside China. What keeps this narrow rather than wide: the company itself names Novartis (asciminib), Takeda (ponatinib) and AbbVie (venetoclax) as direct competitors on the same targets, nothing is approved outside China, prices in the only market where it sells are set through a national reimbursement negotiation the company does not control, and patents expire.

Demand for leukemia treatment does not follow the economic cycle: patients with chronic myeloid leukemia or CLL/SLL need therapy regardless of what GDP is doing, and treatment is often continuous over years. What actually moves the numbers here is regulatory and administrative, not macroeconomic — new approvals, new indications, and above all inclusion in China's National Reimbursement Drug List. The company's own account of 2025 attributes Olverembatinib's growth to the NRDL taking effect for all its indications in January 2025 and Lisaftoclax's contribution to its July 2025 launch. That cuts both ways: reimbursement listing expands the treatable pool by making the drug affordable, but the price is negotiated down as a condition, and China also runs volume-based procurement. A beginner should read revenue swings at this company as driven by approvals, reimbursement decisions and the timing of licensing payments, not by the business cycle.

Wichtigste Risiken

• Persistent losses and no assurance of profitability — The company reports net losses of RMB 1,243.0 million in 2025, RMB 405.7 million in 2024 and RMB 925.7 million in 2023, and accumulated losses of RMB 7,013.3 million at December 31, 2025. It states it expects substantial and increasing losses for the foreseeable future as it develops and seeks approvals for its candidates, and that it may never become profitable or sustain profitability even if it reaches it.
• Need for further financing and dilution — The company says its RMB 2,470.1 million of cash and its loan facility should fund at least the next twelve months but may not carry any candidate through regulatory approval, which can take several years. It expects to need substantial additional financing; raising it may dilute shareholders, restrict operations or force it to give up rights to products or candidates, and its credit facility may not be available on the same terms as in the past.
• Everything depends on two drugs — The filing states the company is substantially dependent on the commercial success of Olverembatinib and Lisaftoclax, and that if it cannot maintain or increase their sales its revenue and financial condition will suffer. It also notes it has a limited history of generating revenue on which to judge its future performance, and limited commercialization experience.
• No approval outside China — The company discloses that outside China it has obtained no marketing authorization for any candidate. Clinical development is inherently uncertain, earlier results may not predict later ones, and the FDA, EMA and other regulators may decline to accept data from trials run in other jurisdictions — a live issue given that much of the Olverembatinib evidence is Chinese.
• Dependence on partners it does not control — The filing warns that Takeda may change the terms of the exclusive licence, terminate the option agreement at its sole discretion on written notice, or simply never exercise its option, and that Innovent has termination rights under the Olverembatinib collaboration. The company also relies on third parties to manufacture part of its drug supply and to run its preclinical studies and clinical trials, including investigator-initiated ones.
• Intellectual property may not hold — The company states that if it cannot protect and defend its proprietary technology or obtain and maintain patent protection, competitors could develop and sell similar or identical drugs. It also notes that patent applications are published only about eighteen months after the priority date, so third parties may already have filed on similar compounds without its knowledge.
• China listing, PCAOB and delisting risk — Because its operations are in China, the company flags that if the PCAOB cannot fully inspect its China-based auditors and the SEC identifies it as a Commission-Identified Issuer for two consecutive years under the Holding Foreign Companies Accountable Act, its ADSs would be delisted from Nasdaq and barred from trading in the US. It also flags Cyberspace Administration of China oversight over data security, restrictions on transferring scientific data abroad, PRC approval or filing requirements for future capital raising, and rising US–China trade and geopolitical tension.
• Manufacturing and growth management — The company states that if its manufacturing facilities are damaged, destroyed or interrupted its business and prospects would be hurt, that it has sharply expanded its research, manufacturing and commercial capabilities and may struggle to manage that growth, and that failing to comply with applicable regulations or to obtain and keep the necessary licences and permits could damage its reputation and results.

Die größten Kunden machen 76.1 % des Umsatzes aus

Extremely concentrated. The filing's note on major customers shows one customer, 'Customer A', accounting for RMB 436.6 million (US$62.4 million) of the RMB 574.1 million of 2025 revenue — about 76%. In 2024 the picture was different again: a single counterparty, 'Customer B', brought in RMB 678.4 million, the whole of that year's intellectual property income. The concentration shows up in the balance sheet too: the company discloses that 68% of trade receivables were due from its largest customer at the end of 2025 (73% in 2024), and 91% under a second measure (96% in 2024). The company distributes its drugs through third-party distributors including Innovent, so a large distributor sitting between it and the hospitals is the structural reason a single 'customer' can be three quarters of revenue.